FindMeCure Ltd., a company focused on bringing clinical trials closer to patients, is pleased to announce a new member of their board of advisors as of July 2019 – Dr. Montserrat Barcelo Riera. This decision has been driven by the company’s strategic expansion in new areas of the clinical research industry and Montserrat’s professional experience in business growth and global operations.
About Dr. Montserrat Barcelo Riera
Dr. Barcelo is a leading figure in the global contract research industry and has been with TFS for the last 13 years. TFS is a top mid-sized full-service CRO dedicated to global clinical research with local presence and expertise. Dr. Barcelo has been the first employee outside of TFS headquarters in Sweden and played a key role in the company’s success to a leading European and later global CRO. She was also a member of the board of advisors within the company. Dr. Barcelo is also one of the founders of EjeCon, an organization of more than 700 women that are a part of company advisory boards and Board member of the well-known European analytical CRO Kymos Pharma services.
FindMeCure Ltd, a UK-based company, is providing digital patient recruitment support and has been growing rapidly in the last years, supporting companies, such as Parexel, Covance and Syneos Health. FindMeCure Ltd. has also been assisting sponsor companies, such as Merck and BMS in developing patient-centric clinical trial designs. Dr. Barcelo is joining FindMeCure Ltd. in a key moment of its development, as FindMeCure Ltd. released their new product FindMePatients - an analytics platform dedicated to identifying country-specific challenges and opportunities in order to avoid delays with patient recruitment. This platform is the company’s next step in speeding up clinical trials and ensuring faster access to promising new treatments.
As a part of FindMeCure Ltd., Dr. Barcelo will be involved in the support of FindMePatients and its goal to improve patient recruitment. FindMePatients is designed to support Pharma, Biotech and CROs’ strategic clinical trial planning on a global level and in alignment with patients’ expectations and local regulations.